33
Participants
Start Date
August 9, 2019
Primary Completion Date
August 12, 2020
Study Completion Date
August 12, 2020
CXA-10
(10-nitro-9(E)-octadec-9enoic acid)
NYU Langone Medical Center, New York
Allegheny General Hospital, Pittsburgh
University of Pennsylvania, Philadelphia
Washington Hospital (Medstar), Washington D.C.
George Washington Medical Faculty Associates, Washington D.C.
Inova Medical Campus, Falls Church
University of Virginia School of Medicine, Charlottesville
Sentara Medical Group, Norfolk
Duke University, Durham
Mayo Clinic, Jacksonville
University of Florida Health, Gainesville
University of Miami, Miami
University of Alabama, Birmingham
Vanderbuilt University, Nashville
The Ohio State University, Columbus
Cleveland Clinic, Cleveland
Christ Hospital-Lindner Research Center, Cincinnati
Indiana University, Indianapolis
Froedert Medical College of Wisconsin, Milwaukee
University of Minnesotta, Minneapolis
University of Chicago, Chicago
Washington University and Barnes Jewish Hospital, St Louis
University of Kansas, Kansas City
UT Southwestern, Dallas
Houston Methodist, Houston
Texas Tech, El Paso
National Jewish Health, Denver
University of Arizona, Tucson
University of California San Diego, La Jolla
Anaheim Clinical Trials, LLC, Anaheim
University of California San Francisco, San Francisco
Golden Jubilee National Hospital, Glasgow
Royal Free, London
Royal Brompton, London
Hammersmith Hospital, London
Freeman Hospital, Newcastle upon Tyne
Royal Hallamshire Hospital, Sheffield
Lead Sponsor
Collaborators (2)
Medpace, Inc.
INDUSTRY
Innovative Analytics
UNKNOWN
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
OTHER
Complexa, Inc.
INDUSTRY